homepage-top-section

The agreement covers the promotion license, sales, and distribution of CARTISTEM. MEDIPOST will supply the drug substance and retain manufacturing rights, while the exclusive rights for the Japanese

The approval covers all existing indications for Rybrevant. The SC formulation reduces administration time from several hours to five minutes, compared to intravenous (IV) delivery, offering increased patient

This is claimed to become the first fully dedicated small-interfering RNA (siRNA) enzymatic-ligation manufacturing facility. The facility expansion is intended to increase capacity, lower production expenses, and enable

The investment values Swixx at more than €1.5bn ($1.76bn). Swixx operates as a commercialisation platform for pharma companies, focusing on markets where those companies have chosen not to

The Digital Acceleration of Toxicity Assessment with Mechanistic and AI-driven Predictions (DATAMAP) project, in collaboration with Baylor College of Medicine, Amgen, Torch Bio and Cincinnati Children’s Hospital Medical

The initiative aims to enhance biotechnology research and innovation in the region. The new memorandum of understanding (MOU) was signed to mark the 15-year collaboration between the two

In October 2025, the two companies signed the deal as part of their focus on bispecifics and ADCs. The agreement aims to expedite the worldwide development and commercialisation

This applies to patients previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. The approval broadens Jaypirca’s label to cover patients at an earlier stage of treatment

The therapy is intended for patients who have undergone at least three previous therapies, including an immunomodulatory agent and a proteasome inhibitor. The approval is the first authorisation